
MC1742
CAS No. 1776116-74-5
MC1742( —— )
Catalog No. M34786 CAS No. 1776116-74-5
MC1742 is an inhibitor of class I histone deacetylases (HDACs; IC50s = 0.1, 0.11, 0.02, and 0.61 μM for HDAC1, -2, -3, and -8, respectively) and class IIb HDACs (IC50s = 7 and 40 nM for HDAC6 and HDAC10, respectively).
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
500MG | Get Quote | Get Quote |
![]() ![]() |
1G | Get Quote | Get Quote |
![]() ![]() |
Biological Information
-
Product NameMC1742
-
NoteResearch use only, not for human use.
-
Brief DescriptionMC1742 is an inhibitor of class I histone deacetylases (HDACs; IC50s = 0.1, 0.11, 0.02, and 0.61 μM for HDAC1, -2, -3, and -8, respectively) and class IIb HDACs (IC50s = 7 and 40 nM for HDAC6 and HDAC10, respectively).
-
DescriptionMC1742 is a potent HDAC inhibitor, with IC50s of 0.1 μM, 0.11 μM, 0.02 μM, 0.007 μM, 0.61 μM, 0.04 μM and 0.1 μM for HDAC1, HDAC2, HDAC3, HDAC6, HDAC8, HDAC10 and HDAC11, respectively. MC1742 can increase acetyl-H3 and acetyl-tubulin levels and inhibits cancer stem cells growth. MC1742 can induce growth arrest, apoptosis, and differentiation in sarcoma CSC.
-
In VitroMC1742 (compound 1) (0.5 and 2 μM; 24 hours) increases acetylation in a dose-dependent manner, observable as punctuate nuclear staining of acetyl-histone H3.MC1742 (0.5, 1 and 2 μM; 24, 48 and 72 hours) significantly induces apoptosis of all CSC cultures.MC1742 (0.025-0.5 μM; 14 days) enhances bone nodule formation in a significantdose-dependent manner.Immunofluorescence Cell Line:Sarcoma cancer stem cells Concentration:0.5 and 2 μM Incubation Time:24 hours Result:Increased acetylation in a dose-dependent manner, observable as punctuate nuclear staining of acetyl-histone H3.Apoptosis Analysis Cell Line:Sarcoma cancer stem cells Concentration:0.5, 1 and 2 μM Incubation Time:24, 48 and 72 hours Result:Significantly induced apoptosis of all CSC cultures.Cell Differentiation Assay Cell Line:Sarcoma cancer stem cells Concentration:0.025, 0.05, 0.1 and 0.5 μM Incubation Time:14 days Result:Successfully enhanced bone nodule formation in a significantdose-dependent manner.
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1776116-74-5
-
Formula Weight395.47
-
Molecular FormulaC21H21N3O3S
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 200 mg/mL (505.73 mM; Ultrasonic )
-
SMILESS(CCCCC(NO)=O)C=1NC(=CC(=O)N1)C2=CC=C(C=C2)C3=CC=CC=C3
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Di Pompo G, et al. Novel histone deacetylase inhibitors induce growth arrest, apoptosis, and differentiation in sarcoma cancer stem cells. J Med Chem. 2015;58(9):4073-4079.?
molnova catalog



related products
-
STC-15
STC-15 (example 70) is an orally active METTL3 inhibitor used in the study of proliferative diseases such as cancer and autoimmune diseases.
-
S26131
S26131 behaves as an antagonist on MT1 and MT2 receptors with Ki of 0.5 and 112 nM respectively.
-
Galangin
Galangin is an agonist/antagonist of the arylhydrocarbon receptor, and also shows inhibition of CYP1A1 activity.